Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$322.83 +1.4%	$286.24	$205.87 ▼ $326.03	$42.09B	0.22	859,177 shs	2.05 million shs
INSM Insmed	$99.49 -2.2%	$78.01	$60.40 ▼ $106.83	$18.87B	0.8	2.30 million shs	34.47 million shs
ONC BeOne Medicines	$241.20 -5.2%	$247.90	$141.84 ▼ $287.88	$26.44B	0.3	340,472 shs	400,801 shs
TAK Takeda Pharmaceutical	$15.11 +0.3%	$14.83	$12.80 ▼ $15.43	$48.06B	0.23	1.96 million shs	1.54 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+4.24%	+5.99%	+19.56%	+32.85%
INSM Insmed	0.00%	-3.11%	+42.19%	+30.41%	+48.49%
ONC BeOne Medicines	0.00%	-2.38%	-1.97%	-11.38%	+24,119,999,900.00%
TAK Takeda Pharmaceutical	0.00%	+2.44%	+0.63%	+1.55%	+16.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.2539 of 5 stars	2.4	4.0	0.0	4.3	3.9	2.5	0.6
INSM Insmed	4.0742 of 5 stars	2.5	4.0	0.0	4.3	3.4	1.7	0.6
ONC BeOne Medicines	3.4661 of 5 stars	4.5	0.0	0.0	0.0	3.0	1.7	0.6
TAK Takeda Pharmaceutical	1.1971 of 5 stars	0.0	3.0	2.5	0.0	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.79	Moderate Buy	$337.91	4.67% Upside
INSM Insmed	3.00	Buy	$106.80	7.35% Upside
ONC BeOne Medicines	3.00	Buy	$320.67	32.95% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest INSM, TAK, ALNY, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
6/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$320.00 ➝ $377.00
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
6/11/2025	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$99.00 ➝ $106.00
6/11/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $102.00
6/11/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $119.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.72	N/A	N/A	$0.52 per share	620.83
INSM Insmed	$363.71M	51.89	N/A	N/A	$1.60 per share	62.18
ONC BeOne Medicines	$3.81B	6.94	N/A	N/A	$34.10 per share	7.07
TAK Takeda Pharmaceutical	$30.09B	1.60	$3.18 per share	4.75	$14.39 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	362.73	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	339.72	N/A	-9.40%	-7.55%	-4.42%	N/A
TAK Takeda Pharmaceutical	$712.33M	$0.22	68.66	9.15	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)

Latest INSM, TAK, ALNY, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.64%	N/A	250.00%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
INSM Insmed	11.38	5.86	5.44
ONC BeOne Medicines	0.05	1.96	1.71
TAK Takeda Pharmaceutical	0.57	1.01	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
INSM Insmed	N/A
ONC BeOne Medicines	48.55%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.20%
INSM Insmed	3.00%
ONC BeOne Medicines	6.62%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.82 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

INSM, TAK, ALNY, and ONC Headlines

Recent News About These Companies

Sclerosing Mesenteritis: What GIs Need to Know About This Rare Disease

June 28 at 8:12 AM | medscape.comM

Herbosa cites Dengvaxia lesson as PH mulls approval of Qdenga vaccine

June 28 at 8:12 AM | gmanetwork.comG

Sun Pharma appoints Richard Ascroft as North American CEO

June 27 at 5:08 PM | emjreviews.comE

Lupin gets U.S. FDA nod for generic of Takeda’s constipation drug

June 25, 2025 | thehindu.com

Sun Pharma Announces Appointment of Richard Ascroft as CEO North America

June 25, 2025 | finance.yahoo.com

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

June 25, 2025 | zacks.com

Lupin gets approval from U.S FDA for Prucalopride Tablets

June 25, 2025 | uniindia.comU

Lupin receives USFDA approval for Prucalopride Tablets

June 25, 2025 | business-standard.comB

USFDA okays Lupin Prucalopride Tablets for chronic idiopathic constipation

June 25, 2025 | medicaldialogues.inM

Lupin receives US FDA approval for drug used to treat bowel disorder

June 25, 2025 | cnbctv18.comC

Takeda Announces New Assignments of Directors

June 25, 2025 | businesswire.com

Takeda Pharmaceutical Co Ltd ADR Key Metrics - Morningstar

June 24, 2025 | morningstar.comM

Alagille Syndrome Market Research 2025-2035 | Competitive Analysis of Mirum Pharmaceuticals, Ipsen, and Takeda Pharmaceutical

June 24, 2025 | uk.finance.yahoo.com

Questex’s Fierce Pharma Unveils Powerhouse Conference Program for the Inaugural Fierce Pharma Week, Where Pharma’s Future Takes Shape

June 23, 2025 | finance.yahoo.com

Yousif Capital Management LLC Has $444,000 Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK)

June 21, 2025 | marketbeat.com

Inscription Capital LLC Invests $303,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

June 19, 2025 | marketbeat.com

Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

June 18, 2025 | kxan.comK

Takeda Pharmaceutical Co. (NYSE:TAK) Shares Purchased by QRG Capital Management Inc.

June 18, 2025 | marketbeat.com

Trump rekindles pharmaceutical tariff threat, suggesting import duties could come 'very soon': Reuters

June 17, 2025 | fiercepharma.comF

Class Status Upheld in Takeda, Eli Lilly RICO Suit Over Actos

June 17, 2025 | news.bloomberglaw.comN

GAMMA Investing LLC Has $1.56 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Applied Digital: Now the High-Stakes Race to Build Begins
By Jeffrey Neal Johnson | June 17, 2025
View Applied Digital: Now the High-Stakes Race to Build Begins
Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
By Leo Miller | June 10, 2025
View Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?

INSM, TAK, ALNY, and ONC Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$322.83 +4.58 (+1.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$319.71 -3.12 (-0.97%)

As of 06/27/2025 05:59 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Insmed NASDAQ:INSM

$99.49 -2.25 (-2.21%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$99.50 +0.01 (+0.01%)

As of 06/27/2025 07:45 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

BeOne Medicines NASDAQ:ONC

$241.20 -13.29 (-5.22%)

As of 06/27/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical NYSE:TAK

$15.10 +0.05 (+0.30%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$15.12 +0.01 (+0.07%)

As of 06/27/2025 07:42 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time